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Background: Hepatitis B (HB) infection is common in Mali. However, there is little information on molecular and
biochemical characteristics of HB carriers.
Methods: A group of 1466 adult volunteers was recruited in the district of Bamako. Confirmed HB carriers were
tested for HB viral load by quantitative PCR and HBV was genotyped by sequencing of HBS. Fibrosis and hepatitis
activity were measured using the Fibrotest-Actitest. A mutation of TP53 at codon 249 (R249S), specific for exposure
to aflatoxin, was detected in cell-free DNA extracted from plasma.
Results: Overall, 276 subjects were HBsAg-positive (18.8%). Among 152 subjects tested for HBV load, 49 (32.2%) had
over 104 copies/mL and 16 (10.5%) had levels below the limit of detection. The E genotype was found in 91.1% of
carriers. Fibrotest scores≥ F2 were observed in 52 subjects (35.4%). Actitest scores≥ A2 were detected in 15 subjects
(10.2%) and were correlated with Fibrotest scores (p = 0.0006). Among 105 subjects tested, 60% had detectable levels
of R249S copies (>40 copies/mL plasma).
Conclusion: Chronic HB carriage in adults in Bamako district is well over epidemic threshold. About 1/3 of carriers
have moderate to severe liver fibrosis and 60% have detectable aflatoxin-related TP53 R249S mutation. These results
support introduction of anti-HB therapies to reduce the progression towards severe liver disease.
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Chronic carriage of Hepatitis B Virus (HBV) reaches en-
demic levels (≥8% of the general populations) in many
parts of Sub-Saharan Africa, South East Asia and Latin
America. HB chronic infection is the main attributable
risk factor worldwide for severe chronic liver disease
and, significantly, hepatocellular carcinoma (HCC) [1,2].
In West Africa, where rates of chronic HB carriage in
the general, non-vaccinated populations are 10-18%,
HCC is the leading cancer in males (standardized inci-
dence rates (ASRW) of 15-30/105 person years) and the
third in females (ASRW of 7-15/105 person years) [3].* Correspondence: egormally@univ-catholyon.fr
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unless otherwise stated.Most HCC patients are aged 35–50 and present with ad-
vanced tumors with an average time since first symp-
toms of only 2–3 months. Very few patients are
diagnosed with cirrhosis before HCC detection. A clin-
ical study in The Gambia has shown that, at HCC diag-
nosis, ultrasonography reveals concomitant cirrhosis in
about 65% of the cases, corresponding in many cases to
reactive, rather than precursor cirrhosis [4].
In West Africa, HBV infection mostly occurs peri-
natally through horizontal or vertical transmission and
the rate of carriage by 15 years in non-HB vaccinated
subjects is almost equal to adult rates [5,6]. In The
Gambia, HB carriage is detected in over 90% of patients
with HCC before age 50 [7]. Alcohol is not a significant
risk factor at population level. In association with HBV,
the other main risk factor for HCC is dietary exposure
to aflatoxin-B1 (AFB1), a mycotoxins produced by theThis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Figure 1 Flow chart of subject recruitment and selection for analysis.
1466 subjects were initially recruited. Due to practical reasons in a
resource-constrained context (in which extensive and systematic
follow-up of healthy subjects is not feasible), studies on biomarkers
have been carried out on second or third blood samples collected at
recall of subjects who were confirmed chronic carriers. From the initial
recruitment, a total of 199 subjects reported for the first recall and
carrier status was confirmed for 195 subjects. Among these subjects,
152 reported for a third sample, which was used to measure viral load
(152 subjects) and to perform Actitest/Fibrotest (147 subjects; data on
5 subjects not available due to experimental failure). Among these 147
subjects, DNA could be extracted from the plasma for 105 subjects,
who were tested for R249S, HBX (n = 105), HBe testing (n = 103) or HBV
genotype (n = 90). The reduction in numbers for HBe and HBV genotype
is due to experimental failure.
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foods in semi-arid and tropical regions. Exposure to AFB1
induces a “signature” mutation in the tumour suppressor
gene TP53 (R249S, AGG to AGT at codon 249, arginine
to serine substitution). This mutation has been detected in
about 50% of HCC cases in The Gambia [8]. Using a sen-
sitive and quantitative mass spectrometry method, Short-
Oligonucleotide Fragment Analysis (SOMA), R249S is
also detectable as a marker of current exposure in subjects
exposed to AFB1 in the general population [9].
In Mali, studies in specific population groups (pregnant
women, students, blood donors) reported a variable rate of
HB carriage in adults ranging between 10 and 18% [10-17].
In a cohort of 91 patients receiving treatment for chronic
hepatic diseases in hospital Gabriel Touré (Bamako), 54%
were found to be HB carriers, compared to 4.3% in a
matched group of blood donors used as controls [18]. In
the same center a year-long longitudinal study of 57 pa-
tients with severe chronic liver disease, jaundice and as-
cites were observed to be the main clinical signs. In
these patients mortality over 1 year was 82.5%, with the
three main causes being HCC, abdominal bleeding and
hepatic encephalopathy [19]. In this study, we have ana-
lyzed serological and molecular parameters of HB carriage
in a group of 152 adults unselected for pathological condi-
tions and recruited in outpatients clinics and in several oc-
cupational groups. The 152 participants were confirmed
positive for HBsAg at Center for infectiology Charles
Merieux (CICM) in Bamako, Mali. Carriers were tested
for fibrosis status and hepatitis activity by Fibrotest-
Actitest and the presence of mutated TP53 R249S
DNA, a marker of mutagenesis by aflatoxin, in the
serum or plasma.
Methods
Population and recruitment of subjects
A total of 1466 adult volunteers were recruited between
March and September 2009. These volunteers were con-
tacted through on-site information among different groups,
including students (Faculty of Medicine and Pharmacy and
National School for Police, Bamako), university hospital
staff and visitors (Kati hospital; Point G and Gabriel Touré
hospitals in Bamako) (Figure 1). None of the subjects re-
cruited had been referred to this study on the basis of
prevalent hepatic symptoms and none had been previously
tested for HB status. At the start of the study, a blood
sample (4 mL) was obtained by venipuncture using stand-
ard vacutainers. Blood samples were processed immedi-
ately for initial serological tests. A second sample was
obtained at least 6 months after the initial sample. This
second sample was used for confirming the HB carrier
status. Confirmed carriers were requested to complete a
questionnaire with basic demographic information, history
of liver disease and hepatitis. A third sample was obtainedfrom 152 subjects and was used for biochemical and mo-
lecular tests. Molecular analyses were performed using
blood products (plasma) stored at −80°C. Prior to inclu-
sion into the study, subjects received individual informa-
tion by a medical doctor of the Hepato-Gastroenterology
department, Hospital Gabriel Touré and oral informed
consent was obtained. The study protocol was approved
by the ethical committee of INRSP (Institut National de
Recherche en Santé Publique, decision N°09-000008/CE-
INRSP, 19th of May 2009), according to national regula-
tions in Mali.
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All subjects were screened for HBsAg using One-Step
HBsAg test (SD BIOLINE Hepatitis test) and subjects
“positive” with this test were confirmed on an independ-
ent blood sample using VIDAS HBs Ultra (bioMérieux).
Among “negative” subjects with One-Step HBsAg test,
10% were tested using VIDAS HBs Ultra and were all con-
firmed negative. The confirmed HB carrier status was
established by a second, independent test performed on a
blood sample obtained 6 months after the initial analysis.
HBe was detected on a subset of 98 HBsAg + subjects
who presented for a second sample, using ELISA (VIDAS,
bioMérieux). HCV was similarly detected using One-Step
HCV test (SD BIOLINE Hepatitis test).Biochemistry
Confirmed HB carriers who presented for a third blood
sample (at least 6 months after initial testing) were eval-
uated for the status of liver fibrosis and necrotic-
inflammatory hepatitis B using Fibrotest/Actitest [20,21].
These tests were performed at Biomnis (France). Results
were expressed as Fibrosis (F0-F4) and Hepatitis activity
(A0-A3), matched to METAVIR scores as described by
the manufacturer [20].Viral load and HBV genotyping
HB viral load was measured by quantitative PCR (qPCR)
using the COBA AmpliPrep/COBAS TaqMan HBV Test
v2.0 (Roche) as described by the manufacturers using 4 mL
of frozen plasma. Viral load was expressed in number of
HBV copies/mL of plasma. HBV genotyping was per-
formed by sequencing the HBS gene in circulating-free
DNA extracted from plasma (300 μl) using the QIAmp
DNA Blood Mini Kit (Qiagen), as previously described
(Villar et al., [9]). A semi-nested PCR was used to amplify
the entire S gene [22]. The first reaction used 5 μL DNA
with primers S_HBVpol1 (5′-cctgctggtggctccagttca-3′) and
S_HBVporv2 (5′-aaagcccaaaagacccacaat-3′). The PCR re-
actions were performed as described before [22]. The
second step used 1 μL first reaction product and primers
S_HBV123s (5′tcgaggattggggaccctg-3′) and S_HBVporv2.
The PCR reactions were performed as described before
[22]. PCR products (5 μL) were purified using standard
ExoSap-IT enzyme, (USB Corporation) and nucleotide
sequences were determined for both strands by auto-
mated dideoxy sequencing (AbiPrism 3100 sequencer;
Applied Biosystems). Direct sequencing on amplified
fragments used the primers S_HBV123s, S_HBVporv2,
and S_HBV778r (5′-gaggtataaagggactcaag-3′). Alignment
of HBS sequences on HB sequences from database se-
quences were determined using genotyping algorithms
and tools available at HBVRegDB (http://lancelot.otago.ac.
nz/HBVRegDB/index.php?page=Tutorials).Detection of TP53 R249S
Aliquots of the same DNA extracts used for HBS sequen-
cing were used to measure mutant TP53 R249S plasma
concentrations by quantitative SOMA using an internal
standard plasmid [9,23]. Briefly, 228 copies of an internal
standard plasmid were added to all DNA extracts to pro-
vide a reference for quantitation before PCR amplification
of a 93 base-pair segment of exon 7 of TP53 encompass-
ing codon 249. After restriction digestion with HaeIII,
which specifically cuts only the wild-type sequence of
codon 249, the mutated and internal-standard–enriched
PCR products were re-amplified and cut with GsuI to
produce 8-mer oligonucleotides. The latter were purified
and quantitated by HPLC/electrospray ionization tandem
mass spectrometry. Results were expressed as concentra-
tions (copies of R249S/mL plasma). Plasma levels of R249S
DNA ranged from non-detectable to 63,800 copies/mL.
Samples with plasma concentrations > 40 copies/mL were
classified as positive for R249S.
Analysis of HBX gene status in plasma DNA
Detection of truncated versus complete integrated HBX
sequences was performed by PCR as previously described
[24] and modified methods [25,26]. DNA was amplified
by PCR to produce four overlapping amplicons from HBX
of 139, 192, 334 or 425 bp. The 425 bp amplicon encom-
passes the entire HBX sequence and the three shorter
amplicons correspond to fragments initiated at the 5′-end
of HBX and covering progressive lengths of its sequence.
Amplification of all four fragments signals the presence of
a complete HBX, whereas amplification of one or several
shorter fragments signals the presence of 3′-truncated
HBX. The same forward primer X1F was used in each re-
action (5′-GGGACGTCCTTTGTCTACGT-3′). The four
reverse primers were X1R (5′-GGGAGACCGCGTAAA-
GAGAG-3′), X2R (5′-GTGCAGAGGTGAAGCGAAGT-
3′), X3R (5′-CCCAACTCCTCCCAGTCTTT-3′) or X4R
(5′-GGCAGAGGTGAAAAAGTTGCA-3′). PCR condi-
tions have been described previously [27]. The identity of
all PCR products was confirmed by a second PCR and
sequencing.
Statistical analysis
Univariate Chi-square tests and p-values, Fisher-Exact
tests and Odd Ratio (OR) calculations were carried out
using the statistical analysis tools available at http://vassar-
stats.net/. A p value ≤0.05 was considered as significant.
Results
Characteristics of HB carriers
Figure 1 summarizes the recruitment of subjects and the
number of subjects tested for the various biomarkers mea-
sured. Of the 1466 subjects who volunteered for this
study, a total of 276 (18.8%) were identified as HBsAg +
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firmed using a standard reference test (VIDAS, bioMér-
ieux). Of these 276 subjects, a total of 199 provided an
additional blood sample at least 6 months after the initial
screening sample and 195 of them were re-confirmed to
be HBsAg+. These subjects are therefore identified “con-
firmed HB carrier”. The recruitment and demographic
characteristics of these subjects are listed in Table 1. The
average age was 35.1 ± 11.1 (range: 18–69 years) and the
gender ratio (M/F) 2.68:1. Of these subjects, 110 (52.4%)
were recruited among persons attending hospital out-
patient clinics (including mostly patient’s family members
and visitors) at Hospital Gabriel Touré and Point G,
Bamako. The other recruited subjects were members of
several specific groups (military staff, medical students
and health staff ). The majority of the subjects were civil
servant (118; 60.5%), followed by students (45; 23.1%).
HB carriage in the different recruitment groups was 16.8%
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Primary school students 4 2.1
Workers 3 1.5
Others 4 2.1
*Recruited at hospital’s general admission.health staff, and 23% among hospital attendants (P = 0.021,
Chi-square Test).
Among the 195 HB carriers, a group of 152 subjects re-
ported for a third sample, which was used for quantitation
of viral load in the plasma using qPCR. The average viral
load was 3.2 ± 1.7 log10 . HBV DNA was undetectable in
16/152 subjects (10.5%), whereas a load >104 copies/mL
plasma was detected in 49/152 subjects (32.2%) (Table 2).
Among these 152 subjects, HBeAg status was available for
98 subjects. A total of 7 subjects were tested positive for
HBe (7.1%). Of note, these 7 subjects had a viral load ≥ 107
copies/mL, underlining the strong correlation between
viral load and HBe + status. HCV was detected using a
rapid screening test in 44 of the initial group of 1466
volunteers (3%) (data not shown). Among the 152 HB
carriers who were assessed for molecular markers of
HB infection, only one was also HCV-positive.
Genotyping and analysis of HBX status
Complete HBS sequences were generated for 90 sub-
jects. A total of 82 (91.1%) were classified as HBV geno-
type E. A further 5 subjects (5.6%) showed sequences
which matched both E and D genotypes. Three subjects
were found to carry either D4 (1 subject) or A3 (2 sub-
jects) genotypes. There was no difference between age
and biochemical parameters of liver disease according
to different genotypes. HBX gene status (complete se-
quence or 3′ truncated) was analyzed by PCR in 105
subjects. Only 6 subjects (5.7%) had undetectable HBXTable 2 HBe status (n = 103), HBV viral load (n = 152) and
TP53 R249S mutant DNA plasma concentration in
confirmed HB carriers






Non-detectable (Log 1) 16 10.5
10 -10,000 (Log1 - < log4) 87 57.2










Traoré et al. BMC Infectious Diseases  (2015) 15:180 Page 5 of 8sequences. Complete sequences were detected in 60
(57.1%) and truncated sequences in 39 (37.1%) subjects.
Biochemical characterization of hepatitis and liver disease
Fibrotest-Actitest was performed in 147 subjects (Table 3).
Results were expressed as conversion in METAVIR scores
(F0-F4 for Fibrotest and A0-A3 for Actitest). For Fibrotest,
Fibrosis scores from F0 to F1 were considered as “minimal
or absent fibrosis”, F1-F2 to F2 as “moderate fibrosis” and
F3 to F4 as “severe fibrosis”. Whereas a total of 95 subjects
(64.6%) were scored as having minimal or absent fibrosis,
33 subjects (22.5%) were scored as having moderate and
19 (12.9%) severe fibrosis. Thus, a total of 35.4% had sig-
nificant biochemical signs of fibrosis. There was no correl-
ation between the distribution of these three score groups
and viral load (p = 0.801, Chi square test). For Actitest,
viral necrotic-inflammatory activity scores A0 –A1 were
considered as “minimal or absent activity”, A2 as “moder-
ate activity” and A3 as “high activity”. 132 subjects (89.8%)
were scored as having minimal or absent activity, 10
(6.8%) as having moderate activity and 5 (3.4%) as having
high activity. There was no statistically significant associ-
ation between Actitest scores (grouped into two categor-
ies, minimal/absent vs moderate/high) and viral load
(either <104 or ≥ 104, p = 0.18, Fisher Exact test). In con-
trast, there was a strong correlation between Fibrotest and
Actitest scores (each grouped as dichotomized vari-
able, minimal/absent vs moderate/severe or high). TheTable 3 Conversion to METAVIR score of Fibrotest-Actitest
in 147 confirmed HB carriers


















Total 147 100.00OR for having F scores ≥ 2 was 9.2 (95% CI [2.5-34.4])
in subjects with A scores ≥ 1, as compared with sub-
jects with A and F scores falling in the “minimal/ab-
sent” category (P = 0.000267, Fisher Exact test). On the
other hand, F scores were associated with HBX gene sta-
tus. OR for having F scores ≥ 2 was 4 (95% CI [1.6-9.9]) in
subjects with complete HBX sequences as compared to
subjects with truncated sequences (P = 0.0019, Fisher
Exact test). In contrast, there was no significant associ-
ation between A scores ≥2 and HBX status.
Detection of R249S and HBX gene status in plasma DNA
The distribution of mutant TP53 R249S DNA concentra-
tions detected by qSOMA in free circulating DNA from
the plasma are shown in Table 2. Among 105 subjects
tested, 63 (60%) had detectable R249S in the plasma
(≥40 copies/mL). The mean number of copies in sub-
jects with ≥40 copies/mL was 311 (SD: 340) copies/mL,
with a median of 162 copies/mL (min: 42; max 1784).
There was a borderline tendency for association between
low/undetectable R249S and F scores ≥2. Compared to
subjects with ≥40 R249S copies/mL, subjects with ≤40
copies/mL had an OR of 2.1 (95% CI [0.9-4.8]) of having
moderate to severe fibrosis (P = 0.06; Fisher Exact test).
There was no statistically significant association between
positivity for R249S and HBX gene status (complete or
truncated).
Discussion
We have studied a group of volunteers recruited from
various groups of the population in the district of
Bamako, Mali, for HB carriage (as defined by persistent
HBsAg + status) and we have further characterized sev-
eral molecular, serological and biochemical parameters
in the sub-set of those who were confirmed HB carriers.
The results show that the rate of HB chronic carriage is
high in this study population (18.8%), and that at least 1/
3 of the carriers have significant signs of liver fibrosis
(moderate to severe Fibrotest scores, ≥F2, 35.4%) or ac-
tive hepatitis (viral load ≥ 104 copies/mL, 34.2%). Thus, a
substantial proportion of these HB carriers with clear
signs of active hepatitis might benefit from anti HB-
treatment for reducing the risk of progression towards
severe liver disease or liver cancer, in particular in a
context where HB carriers have detectable mutagenic
exposure to aflatoxin [28-30].
The population recruited for this study includes volun-
teer hospital visitors and members of several occupa-
tional groups, unselected for pathology or condition.
The focus on such defined groups may cause a selection
bias. It should be noted that previous studies in Mali
have been conducted on particular groups of high-risk
(e.g. patients with liver disease, HIV-positive subjects,
[11,18,19]) or low-risk (e.g. blood donors, [10,12,17])
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pregnant women and in women of childbearing age
[13-16]. Studies in blood donors and in healthy women
reported a prevalence of HB carriage ranging between
10 and 18%. The proportion of carriers in the present
study group (18.8%) is therefore in the high range of
these previous estimates and is also among the highest
reported in studies in West Africa. Rates between 11
and 17% have been consistently observed in studies per-
formed in The Gambia or in Senegal [4,7,31]. However,
most of these studies have been carried out on selected
“control” groups and data from The Gambia are for an
essentially rural population [4,7].
Of note, childhood HB vaccination has been introduced
in the Expanded Program of Immunization (EPI) in Mali
in 2002. It is expected that, provided adequate vaccination
coverage and efficacy, the rate of HB carriage in the
general population will decrease in the next two-three
decades [32].
The volunteers recruited in this study were categorized in
different sub-groups according to their social/professional
status and the context of their recruitment. Rates of HB
carriage of 16.8% and 17% were detected in two profes-
sional groups, respectively, military staff and staff recruited
in a hospital setting (students; nurses and other hospital
staff). In contrast, high rates (23%) were observed in non-
patient volunteers recruited at outpatient clinics in major
hospitals in Bamako city (Hospital Gabriel Touré and Point
G), and the difference between the three recruitment
groups was found to be significant (P = 0.0021). The so-
cial, demographic and health status of subjects in these
“non-patient” subjects recruited in a hospital setting is
not precisely known. We have noted that this group is
composed of a mixed population with generally lower
socio-economic status than the two professional groups.
Therefore, further studies on the rate of HB carriage in
different strata of the Malian population are needed. It
is indeed possible that the rate of carriage might be
even higher than the average reported here in less-
economically favored groups of the population.
The structure of the study was such that subjects who
were tested as HBsAg + at initial recruitment (276 posi-
tive subjects) were recalled for subsequent blood sam-
ples for other analyses at different time point in the
study. Only part of the initial HBsAg + group was avail-
able for these subsequent analyses, which were thus car-
ried out among subjects from a smaller series of 195
confirmed HB carriers (Figure 1). Thus, we cannot rule
out a selection bias due to compliance with recall. How-
ever, there is no indication that a particular recruitment
sub-group was more represented in the recall group
than in the initial recruitment population.
Based on alignment of HBS sequences with reference
database sequences, the most common HBV genotype inHB carriers was genotype E, present in 91.1% subjects. A
small number of subjects were carriers of either D or A
genotypes, and 5 subjects had sequences that matched
both genotype E and D. The dominance of genotype E in
this population is in agreement with studies in other West
African populations. The only subject with A genotype
had the A3 variant, a sub-genotype documented in West
African populations [33]. The presence of both genotype
E and D sequences in about 5.6% of the subjects is sug-
gestive of either co-infection or recombination between
these genotypes, an event that has been shown in a small
number of infected subjects in different populations of
West Africa [33].
Monitoring of HBV viral load is the most widely used
method in assessing liver disease severity, predicting cir-
rhosis and HCC, deciding initiation of antiviral therapy,
assessing treatment response and detecting the emergence
of drug resistance. In this cohort, 89.5% of HBsAg + sub-
jects (136/152) had detectable HBV viral load, with an
average at 3.2 ± 1.7 log10 IU/mL and 32.2% (49/152) had
loads over 4 log10 IU/mL, considered as cutoff value for
high viral loads. Although there was an overall high cor-
relation between HBe + status and viral load, over 75% of
the subjects with viral load ≥4.0 log10 UI/mL were nega-
tive for HBe, an observation compatible with previous
studies on HB carriers in The Gambia [34]. No previous
data is available for chronic HB carriers in Mali. In
Senegal, a study on 225 HB carriers recruited in a hospital
setting in Senegal (Dakar) has detected an average viral
load of 3.6 log10 IU/mL and 22% had viral loads ≥4.2 log10
UI/mL [35].
The use of Fibrotest and Actitest as surrogate end-
point to assess inactive HB carrier status and to predict
liver disease-free survival has been evaluated in a cohort
of 1,074 patients that includes 47% of patients of African
origin [20]. This study showed that subjects with F
scores ≤ 2.9 (corresponding to ≤ F1 status) and A
scores ≤ 2.7 (corresponding to ≤A1) had 100% of HB-
complication-free survival after 4 years of follow-up, and
that F scores outperformed combined classical predic-
tors such as HBe antibody status, low AST activity, low
viral load and absence of co-infections with HIV, HCV
or HDV. Thus, normal Fibrotest and Actitest values have
been proposed as criteria for a new definition of inactive
HB carrier status. In the present study, of 100 subjects
with complete data for viral load, Fibrotest and Actitest,
35 (35%) matched these criteria of inactive carrier status.
Of these subjects, 8 (22.9%) had a viral load ≥ 4 log10 IU/
ml. On the other hand, of 147 subjects tested by Fibrot-
est, 33 and 19 were scored as having moderate or severe
fibrosis, respectively, representing together over 1/3 of
the study participants (35.4%). There was no significant
correlation between F scores and viral load. Regarding
Actitest, 15 subjects had A status ≥ 2 (10.2%) and this
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IU/mL. Overall, 44% of the total number of subjects
tested for viral load, Fibrotest or Actitest was scored as
“positive” for at least one of the three tests. These obser-
vations suggest that a substantial proportion of HB car-
riers in the population may benefit from treatment with
nucleoside analogs such as Adefovir or Tenofovir [36].
However, there is controversy on whether Fibrotest may
represent an accurate method for the diagnosis of fibro-
sis in West-African HB carriers. A study in Dakar on
HB carriers with normal AST levels and high viral load,
found discordant results for the prediction of fibrosis
using Fibrotest, Fibrometer (another biochemical test) or
Fibroscan (liver stiffness measurements) [35]. It should
be noted that markers such as Haptoglobin, included in
both Fibrotest and Actitest, are strongly expressed in
subjects infected by chronic malaria and sickle cell an-
aemia [37], two prevalent conditions in Bamako. There-
fore, further studies taking into account the specific
epidemiological context are needed to determine an ap-
propriate algorithm for decision of initiating anti-viral
treatment in West African populations.
Levels of TP53 mutation at codon 249 (R249S) in
circulating-free DNA from plasma have been proposed as a
direct biomarker for the mutagenic effect of aflatoxin in
normal subjects exposed through the diet. This mutation is
present at high levels (>2500 copies/mL plasma) in liver
cancer patients and its presence at such levels is concordant
with mutation status in HCC tissues [38]. However, in
asymptomatic subjects from The Gambia, low levels of
R249S (70–2500 copies/mL) have been reported in subjects
from the general rural population, with seasonal variations
that may reflect variations in dietary intake of contaminated
food [22]. In the present study, we have observed that about
60% of HB carriers from Bamako had R249S levels above
threshold values (40 copies/mL), a proportion that is similar
to HB carriers in rural Gambia. However, in subjects from
Bamako, plasma concentrations (311 ± 340) were lower
than in carriers from rural Gambia, in whom mean R249S
levels detected at different periods of the year varied be-
tween 480 and 5,690 copies/mL serum. Overall, these re-
sults suggest that carriers form Bamako may have less
exposure to aflatoxin than carriers from rural Gambia. This
difference may reflect the combined effect of differences in
dietary patterns in urban Bamako and rural Gambia, as
well as the effect of interventions aimed at reducing crop
contamination by aflatoxin, which are taking place in Mali
since the mid 1990’s.
Conclusion
In conclusion, this study provides a detailed assessment of
HB chronic infection status in a group of subjects, unse-
lected for clinical symptoms, in Bamako-Mali. Previous
studies in Mali and in West Africa have mostly addressedHB status in specific groups such as blood donors
[10,12,17], pregnant women [13,16], or patients diagnosed
with chronic active hepatitis [35]. The results show that
the rate of HB carriage in the population of Bamako is in
the higher range of estimates for West Africa, and that
about 30% of adult carriers have HB and/or liver bio-
markers that would qualify them for treatment with HB
anti-viral therapies. On the other hand, mean levels of
mutant R249S DNA, a marker of exposure to aflatoxin,
are significantly lower than those measured in rural
Gambia, where aflatoxin-contaminated crops are an im-
portant component of the diet. Future studies are needed
to assess importance of these factors for the risk of fatal
liver disease and liver cancer in the general population of
Bamako/Mali, in a context of epidemiological transition.
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